U1 snRNP Modulation for Premature Polyadenylation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for assessing the role of U1 snRNP in gene expression and protection against premature cleavage and polyadenylation (PCPA) are limited, and there is a need for comprehensive understanding of its function in regulating mRNA transcriptome diversity.
Innovation Solution
Regulating U1 snRNP activity or level in cells using agents such as U1 agonists or antagonists to modulate gene expression by protecting nascent transcripts from PCPA, thereby influencing mRNA length and isoform expression, and affecting cellular phenotypes like oncogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If U1 snRNP activity is increased to protect nascent transcripts from premature cleavage and polyadenylation, then mRNA transcript length is extended and gene expression is regulated, but device complexity and measurement precision requirements increase
Solution Approach 1:
U1 snRNP acts as an intermediary protective factor that binds to nascent transcripts and prevents premature cleavage and polyadenylation by other cellular machinery, thereby extending mRNA transcript length and regulating gene expression without requiring direct manipulation of the transcription or polyadenylation processes themselves
2Reliability
If U1 snRNP activity is modulated to extend mRNA transcripts, then gene expression regulation is improved, but difficulty of detecting and measuring increases
Solution Approach 1:
The invention modulates U1 snRNP activity levels as a controllable parameter to achieve desired effects on mRNA transcript length and gene expression, allowing researchers to tune the protective effect and associated regulatory outcomes by adjusting U1 snRNP concentration or activity state
3Productivity
If U1 snRNP level is decreased to shorten mRNA transcripts, then oncogenicity is promoted through transcript shortening, but loss of information about full-length transcripts occurs
Solution Approach 1:
U1 snRNP levels and activity are dynamically adjusted to control mRNA transcript length in a temporal and spatial manner, allowing cells to transition between different transcript isoforms with varying 3' UTR lengths, thereby regulating gene expression and oncogenicity while preserving information through alternative splicing patterns
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a novel mechanism for regulating gene expression and cellular phenotypes by extending or shortening mRNA transcripts, which can inhibit or promote oncogenicity, and is applicable in treating diseases like cancer and autoimmune disorders.
Implementation Method 1
U1 plays an essential role in defining the 5′ splice site (ss) by RNA:RNA base pairing via U1 snRNA's 5′ nine nucleotide (nt) sequence
Data Source
AI summary
The invention provides a method of regulating U1 activity associated with its splicing role as well as its role in protecting pre-mRNAs from premature termination by cleavage and polyadenylation, thereby modulating expression of a gene or genes. In one embodiment, the invention includes compositions and methods for regulating gene expression and treating diseases associated with dysregulated gene expression.